BioLife Solutions (BLFS) insider sells 419 shares at $27.36
BioLife Solutions (BLFS) reported an insider transaction by its Chief Quality and Operations officer.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BioLife Solutions (BLFS) reported an insider transaction by its Chief Quality and Operations officer. On 10/09/2025, the reporting person sold 419 shares of common stock at $27.36 per share in a transaction coded “S.” The filing states this sale was made under a Rule 10b5-1(c) trading plan adopted effective 01-03-2023 to satisfy tax withholding obligations upon the vesting of restricted stock.
Following the sale, the reporting person beneficially owned 193,253 shares, held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 419 | $27.36 | $11K |
Footnotes (1)
- F1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BLFS report in this Form 4?
Was the BLFS sale under a 10b5-1 plan?
Who is the BLFS reporting person’s role?
What was the transaction code for the BLFS sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.